Table I.
Relative mRNA levels (mean and standard deviation) for the 2w, 2z, 2× and 2b splice isoforms of PMCA2 in breast tumor tissue vs. adjacent non-tumor tissue by histological and clinical features.
| PMCA2 splice isoform | ||||
|---|---|---|---|---|
| Clinicopathological data | 2w | 2z | 2× | 2b |
| ER statusa | ||||
| Positive (n=55), mean ± SD | 4.14±10.96 | 2.60±5.01 | 2.22±3.09 | 3.25±5.52 |
| Negative (n=23), mean ± SD | 3.64±8.08 | 3.36±4.70 | 2.42±3.69 | 2.11±2.50 |
| P-value | 0.048 | 0.588 | 0.917 | 0.977 |
| PR statusa | ||||
| Positive (n=52), mean ± SD | 2.69±4.27 | 1.77±2.64 | 1.95±2.98 | 3.45±5.68 |
| Negative (n=27), mean ± SD | 6.38±16.12 | 4.77±7.19 | 2.84±3.68 | 1.81±2.19 |
| P-value | 0.352 | 0.024 | 0.215 | 0.717 |
| HER2 statusa | ||||
| Positive (n=36), mean ± SD | 2.62±3.47 | 1.98±3.0 | 2.47±3.44 | 3.90±4.60 |
| Negative (n=18), mean ± SD | 3.11±5.45 | 2.67±3.52 | 1.88±2.52 | 0.175±2.66 |
| P-value | 0.248 | 0.811 | 0.378 | 0.014 |
| Nodal statusa | ||||
| Positive (n=38), mean ± SD | 4.18±13.65 | 2.27±3.82 | 1.65±2.70 | 1.75±1.51 |
| Negative (n=42), mean ± SD | 3.47±4.94 | 3.18±5.65 | 2.74±3.57 | 3.74±6.29 |
| P-value | 0.165 | 0.112 | 0.054 | 0.881 |
| Tumor size (cm)b | ||||
| ≤2 (n=24), mean ± SD | 3.16±5.39 | 3.28±6.97 | 1.97±2.20 | 4.36±7.78 |
| 2–5 (n=45), mean ± SD | 5.09 ± 12.69 | 2.99 ± 3.96 | 2.76±3.91 | 2.46±2.71 |
| ≥5 (n=13), mean ± SD | 0.78±0.66 | 0.89±0.54 | 0.89±0.64 | 1.40±1.50 |
| P-value | 0.100 | 0.07 | 0.168 | 0.476 |
| Histological classificationa | ||||
| Ductal/CDI (n=59), mean ± SD | 4.26±11.48 | 2.58±3.93 | 1.93±2.89 | 2.63±5.27 |
| Lobulillar/CLI (n=26), mean ± SD | 2.59±3.35 | 4.33±9.26 | 3.44±4.70 | 4.27±5.76 |
| P-value | 0.285 | 0.689 | 0.028 | 0.006 |
| Tumor stageb | ||||
| I (n=18), mean ± SD | 3.40±5.81 | 3.32±7.81 | 1.79±2.10 | 4.09±7.88 |
| II (n=35), mean ± SD | 6.34±14.85 | 3.14±4.22 | 3.30±4.47 | 2.61±3.03 |
| III (n=5), mean ± SD | 1.19±1.35 | 1.72±2.61 | 1.13±0.83 | 1.74±1.48 |
| P-value | 0.515 | 0.097 | 0.250 | 0.796 |
To compare variables across different categorical clinicopathological characteristics including ER, PR, and HER2 status, lymph node involvement, and explanatory variables, tumor size, histological classification and stage, the non-parametric Kruskal Wallis test was used, and the Mann Whitney U test was used for pairwise comparison. The pathological staging was conducted as recommended by the American Joint Committee on cancer [Tumor-Node-Metastasis system (21)].
Mann Whitney U test
Kruskal Wallis test. P<0.05 was considered to indicate a statistically significant difference. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; PMCA2, plasma membrane calcium ATPase 2; SD, standard deviation; CDI, carcinoma ductal invasive; CLI, carcinoma lobulillar invasive.